Good Lifestyle

While Ozempic and other drugs as were praised by doctors and celebrities as fast and easy to lose weight, these drugs can be expensive and difficult to get their hands. They also faced reactions on users who sometimes know Side effects . In this spirit, researchers are constantly studying new options that could produce the same dramatic weight loss, without complications - and a team claims to have found this. Read the rest to find out more about a new Nanogel treatment which could potentially reverse obesity without major side effects.

In relation: The new drug has people who lose 60 pounds on average, shows research - and it's not ozempic .

The semaglutide injection ozempic has been approved by the Food and Drug Administration of the United States (FDA) as treatment for people with type 2 diabetes, but it is now prescribed out of AMM for weight loss . This medication, and others like this one works to imitate the Natural Hormone GLP-1, slowing down digestion and reducing appetite. But Ozempic is also known as unpleasant Gastrointestinal side effects , including nausea, diarrhea and constipation.

And there may be more serious complications if it slows digestion too much.

A new Jama The study revealed that Medicines like Ozempic Can cause three severe stomach conditions in patients without diabetes: stomach paralysis, intestinal obstruction and pancreatitis. The reports of these problems even have an impact on users incited a trial To be deposited against Novo Nordisk, the manufacturer of Ozempic, in August, the pursuit alleging that the company demonstrated a "non-increase" of patients of the potential side effect of gastresis or the paralysis of the stomach . AE0FCC31AE342FD3A1346EBB1F342FCB

In September, the FDA Label update For Ozempic, to recognize the relationships of certain people developing the Ileus, which is the medical name of a gastrointestinal disorder which can cause intestinal obstruction.

Now, researchers say they have found a new medication that could have spectacular weight loss results without these disturbing side effects.

In relation: The new drug has people who lose 19% of body weight, according to research - and it is not Ozempic .

Many patients have Order to use ozempic Due to the side effects they have known. But what happens if you could get similar weight loss results without any related problems? This is the question behind what a biomedical engineer of the University of Massachusetts Amherst (Umass) is try to accomplish , Scitechdaily reported.

A biomedical engineer S. Thai Thayumanavan Designed a nanogel delivery system in his laboratory to deliver a drug exclusively to the livestock of the obese mice and reverse their obesity.

"The treated mice have completely lost their weight, and we have not seen any unfortunate side effects", Thayumanavan said in a press release .

In relation: The ozempic patient reveals "a new" atrocious "side effect .

Thayumanavan, who works as director of the Center for Bioactive Delivery at the Umass Institute for Applied Life Sciences (IALS), detailed the conclusions that he and his team discovered with this new drug for An article from August 29 published in the Proceedings of the National Academy of Sciences Nexus newspaper.

Researchers have fed a group of mouse a diet rich in fat, rich in sugar and rich in cholesterol for 10 weeks, doubling their weight. The mice then received a medication every day which was packed in a nanogel and delivered to the mice by intraperitoneal injection (IP).

"We have found a very simple approach, using our unique invention - of the rings that we can direct selectively towards different targets, which we call intelligel," said Thayumanavan. "They were tailor -made for the delivery of hepatocytes in the liver."

After five weeks of treatment, the mice returned to normal weight when they were continuing their regime rich in fat. But the ability to do it effectively while bypassing unwanted side effects is the result of targeted therapy, according to researchers.

"We realized that we had to deliver this medication selectively to the liver, because if this takes place in other places, it could cause complications," said Thayumanavan.

In particular, the team's tests were only carried out at the mouse. But "considering that 100 million Americans have obesity and related cardiometabolic disorders, we have become very enthusiastic about this work," said Thayumanavan.

Now, the efforts to translate these results into humans are pursued by the start-up Cyta Therapeutics, which was also founded in Umass Ials.

"There is a large amount of development work to be carried out between mice and humans," said Thayumanavan. "But we hope it will eventually become a medication."

In relation: For more information, register for our daily newsletter .